Mark S Albom

Improvement in oral bioavailability of 2,4-diaminopyrimidine c-Met inhibitors by incorporation of a 3-amidobenzazepin-2-one group.

K. L. Milkiewicz, S. Miknyoczki, T. Underiner, 2011, Bioorganic & medicinal chemistry.

2,7-Pyrrolo[2,1-f][1,2,4]triazines as JAK2 inhibitors: modification of target structure to minimize reactive metabolite formation.

Jennifer L. Mason, K. L. Milkiewicz, K. Wells-Knecht, 2011, Bioorganic & Medicinal Chemistry Letters.

Synthesis and biological profile of the pan-vascular endothelial growth factor receptor/tyrosine kinase with immunoglobulin and epidermal growth factor-like homology domains 2 (VEGF-R/TIE-2) inhibitor 11-(2-methylpropyl)-12,13-dihydro-2-methyl-8-(pyrimidin-2-ylamino)-4H-indazolo[5,4-a]pyrrolo[3,4-c]

Allison L. Zulli, E. Bacon, B. Ruggeri, 2012, Journal of medicinal chemistry.